January 2026
The Experience and Perspectives of Healthcare Professionals towards Genomic Newborn Bloodspot Screening
Take part in the research study titled "NEWBORN GENomic SEQuencing in screening: Therapy Ready and Information for Life," also known as the TRAIL study.
The TRAIL study is exploring the use of Genomic Newborn Bloodspot Screening (gNBS) as a complement to routine Newborn Screening Programmes. gNBS uses the same dried blood spot card collected 48-72 hours after birth. Similar studies in Australia and Internationally have demonstrated the capacity to screen for over 500 conditions at once - compared to about 25 conditions in routine newborn screening using a single genomic test. This approach enables earlier detection of a wider range of treatable childhood conditions and may also provide important insights into family health.